Neurogene reports initial data from Rett syndrome gene therapy trial
Neurogene has shared initial safety and tolerability results from its ongoing Phase I/II clinical trial of NGN-401, a gene therapy candidate for Rett syndrome. The open-label study is focused on assessing the safety, tolerability, and initial efficacy …